Preview Newsletter

Johnson & Johnson 2Q Media

Traditional Media

Johnson & Johnson beats by $0.03, misses on revenue
Jul 18, 2017 | Seeking Alpha

Johnson & Johnson (NYSE:JNJ): Q2 EPS of $1.83 beats by $0.03.
Johnson & Johnson (JNJ) Tops Q2 EPS by 3c, Raises FY Guidance
Jul 18, 2017 | Street Insider

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $1.83, $0.03 better than the analyst estimate of $1.80. Revenue for the quarter came in at $18.8 billion versus the consensus estimate of $18.97 billion.
Johnson & Johnson Q2 Earnings Rise 3%
Jul 18, 2017 | RTT News

Johnson & Johnson ( JNJ ) released a profit for its second quarter that climbed compared to the same period last year.
Johnson & Johnson ups expectations
Jul 18, 2017 | Associated Press
By Linda Johnson

With a number of acquisitions and new product approvals, Johnson & Johnson looked beyond a dip in second-quarter profit and raised its outlook for the year.
Johnson & Johnson tops profit estimates, but sales fall short
Jul 18, 2017 | MarketWatch

Johnson & Johnson shares JNJ, +1.02% rose 0.6% premarket after the company beat profit estimates for its second quarter, but fell short on sales.
Johnson & Johnson beats on Q2 EPS, misses on revenue
Jul 18, 2017 | Investing.com

Johnson & Johnson (NYSE:JNJ) reported mixed results on Tuesday that beat on the bottom line, but missed on revenue, sending its shares initially 1% higher in pre-market trade.
Johnson & Johnson sees sales growth in near-term; raises 2017 profit forecast
Jul 18, 2017 | Reuters
By Michael Erman and Divya Grover

Johnson & Johnson (JNJ.N) expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as its cancer drugs Darzalex and Imbruvica.
Johnson & Johnson Q2 top line up 2%; earning off 4%; non-GAAP EPS up 5%; guidance raised; shares ahead 2% premarket
Jul 18, 2017 | Seeking Alpha

Johnson & Johnson (NYSE:JNJ) Q2 results ($M): Total Revenues: 18,839 (+1.9%); Consumer: 3,478 (+1.7%); Pharmaceutical: 8,635 (-0.2%); Medical Devices: 6,726 (+4.9%).
J&J lifts earnings guidance; shares drift higher in pre-market trading
Jul 18, 2017 | Financial Times
By Mehreen Khan

Johnson & Johnson, the world’s biggest healthcare group, boasted rising quarterly sales and lifted its earnings guidance for the full-year.
Johnson & Johnson’s medical device sales set the Q2 pace
Jul 18, 2017 | Mass Device
By Brad Perriello

The medical device business at Johnson & Johnson (NYSE:JNJ), the world’s second-largest medtech operation, today posted the highest second-quarter sales growth of its three major divisions, outpacing its pharmaceutical and consumer products segments.
BRIEF-Johnson & Johnson Q2 earnings per share $1.40
Jul 18, 2017 | Reuters

Johnson & Johnson reports 2017 second-quarter results
Johnson & Johnson posts drop in Q2 profit, as sales of prescription drugs flatten
Jul 18, 2017 | FirstWord Pharma
By Joe Barber

Johnson & Johnson announced Tuesday that second-quarter sales of prescription drugs were relatively flat, falling 0.2 percent year-over-year to $8.6 billion, reflecting a negative impact from currency of 1.2 percent.
Johnson & Johnson Raises Guidance
Jul 18, 2017 | Wall Street Journal
By Jonathan D. Rockoff and Anne Steele

Johnson & Johnson JNJ +1.32% raised its sales and profit outlook for the year even as the health-care giant’s second-quarter pharmaceutical revenue declined amid steeper competition for some of its key drugs.
Johnson & Johnson Q2 Profit Down, But Adj. EPS Tops View; Lifts 2017 Outlook
Jul 18, 2017 | RTT News

Johnson & Johnson (JNJ) reported a profit for the second quarter of 2017 that declined 4.3 percent from the last year. But, adjusted earnings per share for the quarter topped analysts' expectations. The company raised its outlook for full-year 2017.
Johnson & Johnson 2017 Q2 - Results - Earnings Call Slides
Jul 18, 2017 | Seeking Alpha

The following slide deck was published by Johnson & Johnson in conjunction with their 2017 Q2 earnings call.
Johnson & Johnson And Harley-Davidson Inc Q2 Earnings Reports
Jul 18, 2017 | Value Walk
By Michelle Jones

The Johnson & Johnson Q2:F17 and Harley-Davidson Q2:F17 earnings reports were released before opening bell this morning. Johnson & Johnson posted adjusted earnings of $1.83 per share on $18.8 billion in sales, compared to the consensus estimates of $1.79 per share and $18.95 billion in revenue. In last year’s second quarter, the company posted $18.48 billion in revenue.
Shares now down at $132.15 (JNJ) Johnson & Johnson Reports 2017
Jul 18, 2017 | First News 24
By Roy Scholtz

The company is so far trading down by -0.37 percent from yesterday’s close.
Johnson & Johnson shares advance as second quarter beats market expectations
Jul 18, 2017 | Proactive Investors
By Jamie Ashcroft

Johnson & Johnson (NYSE:JNJ) shares advanced almost 1% in Tuesday’s premarket deals after quarterly financials beat market expectations.
ANALYST ADVICE AND EARNINGS INSIGHT: JOHNSON & JOHNSON (JNJ), SEATTLE GENETICS, INC. (SGEN)
Jul 18, 2017 | Post Analyst

The recently concluded session had traders exchanging Johnson & Johnson (NYSE:JNJ)low level
Johnson & Johnson Q2 Consumer Sales Rise 1.7%
Jul 18, 2017 | Happi

Johnson & Johnson is reporting sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016.
JNJ Stock: Johnson & Johnson Still a Top Pick for Long-Term Investors
Jul 18, 2017 | Income Investors
By Jing Pan

The thing with dividend stocks like Johnson & Johnson (NYSE: JNJ) is that they don’t really work that well in a conversation at a cocktail party. When asked about your stock market investments, people will likely show more interest when you tell them about an electric car company or a smartphone maker rather than JNJ stock.
Johnson & Johnson (NYSE:JNJ) Issues FY17 Earnings Guidance
Jul 18, 2017 | Daily Political
By Trevor Kearing

Johnson & Johnson (NYSE:JNJ) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $7.12-7.22 for the period, compared to the Thomson Reuters consensus estimate of $7.11. The company issued revenue guidance of $75.8-76.1 billion, compared to the consensus revenue estimate of $75.65 billion.
Johnson & Johnson (NYSE:JNJ) Announces Quarterly Earnings Results
Jul 18, 2017 | Ticker Report
By Stephan Byrd

Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings results on Tuesday. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04, Bloomberg Earnings reports.
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Jul 18, 2017 | The Motley Fool
By Dan Caplinger

Johnson & Johnson (NYSE:JNJ) owes much of its recent success to the strength of its pharmaceutical division.
Johnson & Johnson Shares Slip Following Mixed Earnings
Jul 18, 2017 | 24/7 Wall Street
By Chris Lange

Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted $1.83 in earnings per share (EPS) on $18.8 billion in revenue.
Remicade is ready to fend off biosim No. 2, Johnson & Johnson executives say amid Q2 revenue miss
Jul 18, 2017 | FiercePharma
By Carly Helfand

Johnson & Johnson’s Remicade is holding its own against a U.S. biosimilar rival—so much so, the company says, that it’s not worried about a second entrant, which could arrive later this year.
J&J: Remicade holding up better than expected
Jul 19, 2017 | BioPharma Dive
By Jacob Bell

Johnson & Johnson's blockbuster anti-inflammatory treatment experienced a double-digit drop in sales during the second quarter, but the big pharma cautioned investors not to place too much of that decline on biosimilar competition.
Johnson & Johnson Is Ready to Break Out in a Big Way Despite Lackluster Sales Growth (VIDEO)
Jul 18, 2017 | The Street
By Roberto Pedone

Pharmaceutical player Johnson & Johnson (JNJ) announced earnings this morning before the opening bell for the second-quarter of 2017, and there's a good reason to be bullish on the stock despite incremental sales growth.
Johnson & Johnson (JNJ) Issues FY17 Earnings Guidance
Jul 18, 2017 | Transcript Daily
By Lauren Steadman

Johnson & Johnson (NYSE:JNJ) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $7.12-7.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.11. The company issued revenue guidance of $75.8-76.1 billion, compared to the consensus revenue estimate of $75.65 billion.
Johnson & Johnson Is Delivering
Jul 18, 2017 | Seeking Alpha
By Quad 7 Capital Research

Johnson & Johnson (NYSE:JNJ) has just reported earnings which once again continue to impress here in 2017 which I have described as a key year for the company.
Johnson & Johnson Raises 2017 Sales, Profit Estimate
Jul 19, 2017 | SenegalActu
By Mercedes Poole

Premier, Inc. (NASDAQ:PINC)'s stock on Monday traded at beginning with a price of $36.10 and when day-trade ended the stock finally slumped -1.69% to reach at $35.54. About 161,130 shares traded. The New York-based Braun Stacey Assocs Inc has invested 1.27% in Johnson & Johnson (NYSE:JNJ). It has outperformed by 1.95% the S&P500.
Johnson & Johnson (JNJ) Announces Quarterly Earnings Results
Jul 19, 2017 | Stock Observer
By George Bondi

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday.
Johnson & Johnson (JNJ) Issues FY17 Earnings Guidance
Jul 19, 2017 | Steelers Lounge
By James Hoffman

Johnson & Johnson (JNJ) traded down 0.34% during midday trading on Monday, reaching $132.15. About 12,962 shares traded. It is down 18.83% since July 18, 2016 and is uptrending. It has outperformed by 18.90% the S&P500.
Johnson & Johnson (NYSE:JNJ) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Jul 19, 2017 | WKRB News and Analysis
By Kristian Gore

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04, Bloomberg Earnings reports.
Johnson & Johnson Raises Yearly Sales, Profit Outlook
Jul 19, 2017 | The Street
By Amanda Schiavo

Johnson & Johnson (JNJ) increased its expectations for its yearly profit and sales outlook, after reporting 2017 second quarter financial results on Tuesday morning.
Johnson & Johnson Signals It Could Make Additional Divestitures
Jul 19, 2017 | The Street
By Armie Margaret Lee

More divestitures could be in Johnson & Johnson's (JNJ) future. On an earnings call on Tuesday, July 18, chief financial officer Dominic Caruso noted that among Johnson & Johnson's priorities is to actively manage its portfolio to maximize value.
These 2 Drug Giants In Buy Range Just Beat Earnings Views
Jul 19, 2017 | Investors Business Daily
By Allison Gatlin

Two stocks in buy range — Swiss drugmaker Novartis (NVS) and Dow industrials component Johnson & Johnson (JNJ) — both reported better-than-expected second-quarter earnings early Tuesday.

Television

CNBC Squawk Box
Jul 18, 2017 | CNBC
CNBC Squawk Box
Jul 18, 2017 | CNBC
CNBC Squawk Box Clip (Analyst Analysis)
Jul 18, 2017 | CNBC
Bloomberg Daybreak: Americas
Jul 18, 2017 | Bloomberg
CNBC Squawk Box – Jim Cramer
Jul 18, 2017 | CNBC
CNBC Squawk on the Street
Jul 18, 2017 | CNBC
CNBC Mad Money with Jim Kramer
Jul 19, 2017 | CNBC
By CNBC
CNBC Street Signs
Jul 19, 2017 | CNBC

Traditional Media

Johnson & Johnson beats by $0.03, misses on revenue

Jul 18, 2017 | Seeking Alpha

Johnson & Johnson (NYSE:JNJ): Q2 EPS of $1.83 beats by $0.03.
Revenue of $18.84B (+1.9% Y/Y) misses by $110M.

Shares +1.01% PM.

Return to headline | Return to top
Johnson & Johnson (JNJ) Tops Q2 EPS by 3c, Raises FY Guidance

Jul 18, 2017 | Street Insider

Johnson & Johnson sees FY2017 EPS of $7.12-$7.22, versus the consensus of $7.10.
The Company increased its sales guidance for the full-year 2017 to $75.8 billion to $76.1 billion ( vs consensus of $75.67 billion).
"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA™ as well as the submission and approval of several key line extensions," said Alex Gorsky, Chairman and Chief Executive Officer. "The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson Family of Companies. Together with all of our businesses, we will continue to transform the lives of patients around the world."

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

Return to headline | Return to top
Johnson & Johnson Q2 Earnings Rise 3%

Jul 18, 2017 | RTT News

Johnson & Johnson ( JNJ ) released a profit for its second quarter that climbed compared to the same period last year.
The company said its bottom line rose to $5.02 billion, or $1.83 per share.
This was up from $4.87 billion, or $1.74 per share, in last year's second quarter.
Analysts had expected the company to earn $1.80 per share, according figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company said revenue for the quarter rose 1.9% to $18.84 billion. This was up from $18.48 billion last year.
Johnson & Johnson earnings at a glance:
-Earnings (Q2): $5.02 Bln. vs. $4.87 Bln. last year.
-Earnings Growth (Y-o-Y): 3.1%
-EPS (Q2): $1.83 vs. $1.74 last year.
-EPS Growth (Y-o-Y): 5.2%
-Analysts Estimate: $1.80
-Revenue (Q2): $18.84 Bln vs. $18.48 Bln last year.
-Revenue Change (Y-o-Y): 1.9%

Guidance:

Full year EPS guidance: $7.12 - $7.22

Return to headline | Return to top
Johnson & Johnson ups expectations

Jul 18, 2017 | Associated Press

By Linda Johnson

With a number of acquisitions and new product approvals, Johnson & Johnson looked beyond a dip in second-quarter profit and raised its outlook for the year.
The health care products giant expects sales and profit growth to accelerate this year, with momentum carrying over into 2018. The company, however, expects continued pressure to hold down prices and a weaker market for consumer health products.
With the failure this week to win consensus for the Republican health care plan, CEO Alex Gorsky said Congress needs to create a more stable environment for the industry. But several hours later, GOP efforts to repeal much of President Barack Obama's health care law collapsed.
Saying she could not vote to repeal Obamacare, West Virginia Sen. Shelley Moore Capito said that she "did not come to Washington to hurt people."
Wall Street hates uncertainty and on Tuesday, healthcare stocks were among the biggest losers.
Gorsky is in Washington for meetings with U.S. and global leaders.
Drugmakers understand concerns about drug prices and the need to ensure patients can get needed medicines, but that is only part of the solution, Gorsky said.
"Medicines represent only about 15 percent of health care spending" in the U.S., Gorsky said.
Until this year, however, those in the pharmaceutical industry stressed that prescription drugs accounted for only 10 percent of U.S. health care spending. Steady price increases and many new drugs with price tags exceeding $100,000 per year have pushed that percentage higher.
J&J reported higher spending on marketing, production and research Tuesday, which pushed down second-quarter profit 4.3 percent. That spending will pay off, J&J said.
Shares rose 2 percent in midday trading, while broader markets in decline.
J&J's biggest acquisition ever, a $30 billion deal for Switzerland's Actelion, was completed last month, bringing with it a stable of new medicines, including drugs to treat high blood pressure in the lungs and some experimental drugs in late-stage testing.
Last week, the Food and Drug Administration approved Tremfya, an injected drug for psoriasis, expanding the company's key franchise of treatments for immune system disorders.
The first full quarter of sales after its buyout of Abbott Medical Optics pushed sales in J&J's medical devices business up 5.1 percent.
Net income was $3.83 billion, or $1.40 per share, down from $4 billion, or $1.43 per share, a year earlier.
Adjusted net income was $5 billion, or $1.83 per share, 4 cents better than Wall Street analysts expected. Revenue was $18.84 billion, just shy of analyst expectations.
Sales dipped 0.2 percent to $8.64 billion at its prescription drugs business, its largest segment. Sales of medical devices and diagnostics climbed 4.9 percent to $6.73 billion.
J&J said it now expects full-year earnings in the range of $7.12 to $7.22 per share, up from $7 to $7.15. It forecast revenue in the range of $75.8 billion to $76.1 billion, up from $75.4 billion to $76.1 billion.
"We're going to be launching 10 new brands between now and 2021, several of them with over $4 billion (annual sales) potential," Gorsky said.

Return to headline | Return to top
Johnson & Johnson tops profit estimates, but sales fall short

Jul 18, 2017 | MarketWatch

Johnson & Johnson shares JNJ, +1.02% rose 0.6% premarket after the company beat profit estimates for its second quarter, but fell short on sales. The consumer goods company said it had net income of $3.8 billion, or $1.40 a share, in the second quarter, down from $3.9 billion, or $1.43 a share, in the year-earlier period. Excluding one-time charges, per-share earnings came to $1.83, ahead of the FactSet consensus of $1.79. Sales rose to $18.8 billion from $18.5 billion, below the FactSet consensus of $18.9 billion. The company raised its guidance for the full year and now expects sales of $75.8 billion to $76.1 billion. The current FactSet consensus is for full-year sales of $75.7 billion. The company set EPS guidance for the year of $7.12 to $7.22 a share, compared with a FactSet consensus of $7.11. The stock is up 15% in 2017, while the Dow Jones Industrial Average DJIA, -0.04% has gained 9.5% and the S&P 500 SPX, -0.01% has gained 10%.

Return to headline | Return to top
Johnson & Johnson beats on Q2 EPS, misses on revenue

Jul 18, 2017 | Investing.com

Johnson & Johnson (NYSE:JNJ) reported mixed results on Tuesday that beat on the bottom line, but missed on revenue, sending its shares initially 1% higher in pre-market trade.
The blue chip healthcare products firm said earnings per share (EPS) came in at $1.83 in the second quarter, compared to expectations of $1.80 a share and $1.74 in the same period last year.
The firm’s revenue totaled $18.84 billion in the April-to-June quarter, coming out just under estimates for revenue of $18.93 billion. That compared to sales of $18.48 billion in the second quarter of 2016.
"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year," chairman and chief executive officer Alex Gorsky said in the press release, adding that the company's pharmaceutical pipeline "continued its strong momentum".
Traders will now turn their attention to the bank’s conference call due to start at 8:30AM ET (12:30GMT).
Following the release of the report, shares in Johnson & Johnson rose 1.07% in pre-market trade to $133.50 by 6:50AM ET (10:50GMT). Its shares closed down 0.34% on Monday at $132.15.

Meanwhile, U.S. equity markets pointed to a flat open. The blue-chip Dow futuresadvanced 0.06%, the S&P 500 futures edged down 0.02%, while the tech-heavy Nasdaq 100 futures slipped 0.02%.

Return to headline | Return to top
Johnson & Johnson sees sales growth in near-term; raises 2017 profit forecast

Jul 18, 2017 | Reuters

By Michael Erman and Divya Grover

Johnson & Johnson (JNJ.N) expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as its cancer drugs Darzalex and Imbruvica.
J&J, which reported better-than-expected quarterly earnings and raised its full-year profit forecast on Tuesday, is banking on newer pharmaceuticals to counter slowing demand for some of its older, best-selling products, including Remicade treatment and diabetes drug Invokana.
J&J's shares were up 1.9 percent at $134.61 in midday trading on the New York Stock Exchange.
Chief Executive Alex Gorsky said that when drugs add months or years to patient lives and make significant differences on health outcomes, as with multiple myeloma treatment Darzalex and leukemia drug Imbruvica, the company has experienced less pricing pressure.
Pharmaceutical companies have come under pressure to cut prices from insurers and the federal government. J&J is one of several companies that has said it will keep annual price increases mostly below 10 percent.
President Donald Trump has said that he will work to bring down drug prices and signed an executive order on the topic, though it is not clear how it will work.
J&J is the first among major pharmaceutical companies to release quarterly results, and the report comes a day after a Republican effort to pass healthcare legislation in the Senate collapsed. Gorsky is in Washington, D.C., meeting with U.S. and global leaders to discuss health care related issues.
Excluding special items, the maker of everything from drugs, to medical products to consumer products including Band-Aids earned $1.83 per share in the second quarter, beating analysts' estimates by 3 cents.
While sales in J&J's consumer and medical device divisions rose, sales for pharmaceutical products - its largest business - fell marginally to $8.6 billion.
This is the third quarter in a row that J&J's pharmaceutical sales have fallen short of estimates, RBC Capital analysts said in a research note.
"There appears to be a light at the end of the tunnel," BMO Capital Markets analyst Joanne Wuensch said, citing Darzalex's expanded label and the U.S. Food and Drug Administration's recent nod for J&J's potential blockbuster psoriasis treatment, Tremfya.
J&J reported total sales of $18.84 billion for the second quarter, missing the average analyst estimate of $18.95 billion, according to Thomson Reuters I/B/E/S.

The diversified healthcare company, which completed its $30 billion acquisition of Swiss biotech Actelion (ATLN.S) last month, raised its 2017 profit forecast to a range of $7.12 to $7.22 per share, from $7.00 to $7.15

Return to headline | Return to top
Johnson & Johnson Q2 top line up 2%; earning off 4%; non-GAAP EPS up 5%; guidance raised; shares ahead 2% premarket

Jul 18, 2017 | Seeking Alpha

Johnson & Johnson (NYSE:JNJ) Q2 results ($M): Total Revenues: 18,839 (+1.9%); Consumer: 3,478 (+1.7%); Pharmaceutical: 8,635 (-0.2%); Medical Devices: 6,726 (+4.9%).
Net Income: 3,827 (-4.3%); non-GAAP EPS: 5,017 (+3.1%); 1.40 (-2.1%); non-GAAP EPS: 1.83 (+5.2%).
Company says sales growth will accelerate in H2. Global results negatively impacted by baby care products, but partially offset by domestic OTC products.
2017 Guidance: Revenues: $75.8B - 76.1B from $75.4B - 76.1B; Non-GAAP EPS: $7.12 - 7.22 from $7.00 - 7.15.

Shares are up 2% premarket on light volume.

Return to headline | Return to top
J&J lifts earnings guidance; shares drift higher in pre-market trading

Jul 18, 2017 | Financial Times

By Mehreen Khan

Johnson & Johnson, the world’s biggest healthcare group, boasted rising quarterly sales and lifted its earnings guidance for the full-year.
Shares in the group are drifting 1 per cent higher in pre-market trading on Tuesday after J&J said its second-quarter sales rose 1.9 per cent to $18.8bn compared to the same period last year.
The New-Jersey based company said its adjusted full year earnings per share came in at a better than expected $1.83 (estimate: $1.79) in the period, leading it to raise its full-year adjusted EPS to between $7.12 and $7.22 per share.
Sales guidance for 2017 was also raised to a range of $75.8bn-$76.1bn from a previous $74.5bn-$76.1bn. The maker of Tylenol and Band-Aids – which completed a $30bn deal for Actelion in the quarter – said international sales were up 2.3 per cent, with US sales rising 1.6 per cent in the quarter.
But profits in the quarter slipped, falling to $3.83bn from around $4bn last year. J&J said it took a $800m hit for “after-tax special items” in the quarter.
“Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year”, said Alex Gorsky, chairman and chief executive.

“The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson family of companies”, said Mr Gorsky.

Return to headline | Return to top
Johnson & Johnson’s medical device sales set the Q2 pace

Jul 18, 2017 | Mass Device

By Brad Perriello

The medical device business at Johnson & Johnson (NYSE:JNJ), the world’s second-largest medtech operation, today posted the highest second-quarter sales growth of its three major divisions, outpacing its pharmaceutical and consumer products segments.
The New Brunswick, N.J.-based healthcare titan said its medtech biz posted sales of $6.73 billion for the three months ended June 30, up 4.9% over the same period last year.
Overall profits were $3.83 billion, or $1.40 per share, on sales of $18.84 billion, amounting to a -4.3% bottom-line slide on sales growth of 1.9%. Adjusted to exclude 1-time items, earnings per share were $1.83, 3¢ ahead of the consensus forecast on Wall Street. Analysts on The Street were looking for sales of $18.95 billion.
“Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of Tremfya as well as the submission and approval of several key line extensions,” chairman & CEO Alex Gorsky said in prepared remarks. “The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson family of companies. Together with all of our businesses, we will continue to transform the lives of patients around the world.”
Johnson & Johnson cut the high end of its earnings forecast and lowered its sales outlook for the rest of the year, saying it now expects to post full-year adjusted EPS of $7.12 to $7.22, compared with prior guidance of $7.12 to $7.27, on sales of $75.8 billion to $76.1 billion (down from $76.1 billion to $76.8 billion previously).

JNJ shares ticked up 1.1% to $133.50 apiece today in pre-market trading.

Return to headline | Return to top
BRIEF-Johnson & Johnson Q2 earnings per share $1.40

Jul 18, 2017 | Reuters

Johnson & Johnson:
* Johnson & Johnson reports 2017 second-quarter results:
* Q2 earnings per share $1.40
* Q2 sales $18.8 billion versus I/B/E/S view $18.95 billion
* Q2 earnings per share view $1.80 -- Thomson Reuters I/B/E/S
* Sees FY 2017 adjusted earnings per share $7.12 to $7.22
* Q2 adjusted non-gaap earnings per share $1.83 excluding items
* Sees FY 2017 sales $75.8 billion to $76.1 billion
* J&J - ‍full-year adjusted EPS guidance increased to a range of $7.12 to $7.22
* J&J says worldwide consumer sales of $3.5 billion for Q2 2017 represented an increase of 1.7% versus prior year
* J&J - ‍worldwide medical devices sales of $6.7 billion for Q2 2017 represented an increase of 4.9% versus prior year
* J&J says worldwide pharmaceutical sales of $8.6 billion for Q2 2017 represented a decrease of 0.2% versus prior year
* J&J - excluding items, ‍on operational basis, Q2 worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%
* FY 2017 earnings per share view $7.10 -- Thomson Reuters I/B/E/S
* J&J qtrly worldwide invokana/invokamet sales $‍295 million versus $284 million in Q1
* J&J - qtrly worldwide velcade sales $ ‍290 million versus $280 million in Q1 2017
* FY 2017 revenue view $75.68 billion -- Thomson Reuters I/B/E/S
* J&J - ‍second-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.4 billion
* Q2 worldwide remicade sales $‍1,530 million versus $1,672 million in Q1 2017
* J&J - qtrly worldwide Zytiga sales $ 558‍ million versus $523 million in Q1 2017

* J&J - ‍second-quarter 2017 net earnings included charge for after-tax special items of approximately $0.8 billion

Return to headline | Return to top
Johnson & Johnson posts drop in Q2 profit, as sales of prescription drugs flatten

Jul 18, 2017 | FirstWord Pharma

By Joe Barber

Johnson & Johnson announced Tuesday that second-quarter sales of prescription drugs were relatively flat, falling 0.2 percent year-over-year to $8.6 billion, reflecting a negative impact from currency of 1.2 percent. The company's overall revenue lifted 1.9 percent to $18.8 billion, missing analyst estimates of $18.9 billion, as profit slipped 4.3 percent to $3.8 billion.
"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year," remarked CEO Alex Gorsky.
For the full year, Johnson & Johnson said it now expects sales of between $75.8 billion and $76.1 billion, with the bottom end of the range raised from a prior estimate of $75.4 billion. Meanwhile, annual earnings per share are predicted to be in the range of $7.12 to $7.22 per share, revise upward from an earlier forecast of $7.00 per share to $7.15 per share. Analysts expect full-year sales of $75.7 billion on earnings of $7.11 per share.

More to follow.

Return to headline | Return to top
Johnson & Johnson Raises Guidance

Jul 18, 2017 | Wall Street Journal

By Jonathan D. Rockoff and Anne Steele

Johnson & Johnson JNJ +1.32% raised its sales and profit outlook for the year even as the health-care giant’s second-quarter pharmaceutical revenue declined amid steeper competition for some of its key drugs.
Chief Executive Alex Gorsky said the company expects sales and earnings to accelerate in the second half of the year, as J&J incorporates two key acquisitions and launches new products.
The New Brunswick, N.J., company now expects adjusted earnings for the year of $7.12 to $7.22 a share, up from $7 to $7.15. And it expects sales of $75.8 billion to $76.1 billion, up from $75.4 billion to $76.1 billion.
J&J is the world’s largest health-products company and its sales are considered a bellwether for the industry.
The company has been reshaping its pharmaceutical, medical-device and consumer-health businesses to adapt to patent expiries, pricing pressures and changing consumer preferences.
J&J’s results have also been pressured by a stronger U.S. dollar and weakness in some emerging markets.
Rheumatoid-arthritis drug Remicade, long the company’s top-selling product, has begun facing competition from lower-cost “biosimilar” rivals that analysts expect will erode sales.
Remicade sales dropped 14% in the second quarter to $1.53 billion world-wide. Finance Chief Dominic Caruso said sales have held up well against a biosimilar from Pfizer Inc.,and that most of the drop was due to a tough comparison in the previous year’s quarter, when J&J recorded a positive gain for rebates on Remicade and other drugs.
J&J attributed a $342 million drop in its pharmaceutical sales in the quarter to the same positive gain last year.
Sales of diabetes drug Invokana, another key J&J product, plunged 23% to $295 million in the quarter. And sales of prostate-cancer treatment Zytiga dropped 7.2% to $558 million as a federal probe of charities that help patients pay for drugs chilled financial support to help patients cover their out of pocket costs.
Last month, J&J closed its largest deal ever, a $30 billion acquisition of Swiss drug company Actelion. Mr. Gorsky said J&J sees “great opportunities” to increase sales of Actelion drugs by expanding their use to more patients and around the world.
J&J closed in February on its $4.3 billion purchase of Abbott Laboratories ’ eye-surgery equipment business.
Analysts estimate newly-approved psoriasis drug Tremfya could reach $6.4 billion in yearly sales world-wide, according to Evaluate, a market-intelligence firm. A new rheumatoid-arthritis drug, sirukumab, is estimated to notch $5.5 billion in world-wide sales if approved.
Over all revenue in J&J’s pharmaceutical business, the company’s largest, edged 0.2% lower to $8.64 billion, hurt by foreign-currency challenges. J&J’s medical-devices business recorded a 4.9% increase in sales to $6.73 billion. Consumer-health sales grew 1.7% to $3.48 billion.
In all for the quarter, J&J earned $3.83 billion, or $1.40 a share, down from $4 billion, or $1.43 a share, in the same period a year before.
Revenue rose 1.9% to $18.84 billion.
Excluding certain items, adjusted earnings were $1.83 a share. Analysts had expected $1.80 in adjusted per-share profit on revenue of $18.95 billion.
Corrections & Amplifications
Johnson & Johnson’s pharmaceutical revenue declined in the second quarter. Earlier versions of this article incorrectly stated that second-quarter revenue declined. (July 18, 2017)

Return to headline | Return to top
Johnson & Johnson Q2 Profit Down, But Adj. EPS Tops View; Lifts 2017 Outlook

Jul 18, 2017 | RTT News

Johnson & Johnson (JNJ) reported a profit for the second quarter of 2017 that declined 4.3 percent from the last year. But, adjusted earnings per share for the quarter topped analysts' expectations. The company raised its outlook for full-year 2017.
"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year," said Alex Gorsky, Chairman and Chief Executive Officer.
In Tuesday's pre-market trading, the company's shares are up $1.41 or 1.07 percent to $133.50.
Net earnings for the second-quarter declined 4.3 percent to $3.827 billion from the prior year's $3.997 billion, with earnings per share decreasing to
$1.40 from $1.43 in the previous year.
The latest-quarter result included after-tax intangible amortization expense of about $0.4 billion and a charge for after-tax special items of approximately $0.8 billion. The prior year result included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.7 billion.
Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the quarter were $5.0 billion and adjusted earnings per share were $1.83, representing increases of 3.1% and 5.2%, respectively, as compared to the same period in 2016. On an operational basis, adjusted diluted earnings per share also increased 6.9%. Analysts polled by Thomson Reuters expected the company to report earnings of $1.80 per share for the second-quarter. Analysts' estimates typically exclude special items.
"The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson Family of Companies," said Alex Gorsky.
Quarterly sales were $18.84 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Analysts expected revenue of $18.95 billion for the quarter.
Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.
Worldwide Pharmaceutical sales of $8.6 billion for the second quarter 2017 represented a decrease of 0.2% versus the prior year with an operational increase of 1.0% and a negative impact from currency of 1.2%. Domestic sales decreased 2.6%; international sales increased 3.3%, which reflected an operational increase of 6.1% and a negative currency impact of 2.8%.

Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 2.6% and international sales increased 5.1%. Worldwide operational sales growth was negatively impacted by approximately 4 points due to a positive adjustment of U.S. rebate accruals in the second quarter of 2016, which did not repeat in the second quarter of 2017.

Return to headline | Return to top
Johnson & Johnson 2017 Q2 - Results - Earnings Call Slides

Jul 18, 2017 | Seeking Alpha

The following slide deck was published by Johnson & Johnson in conjunction with their 2017 Q2 earnings call.

View slides here.

Return to headline | Return to top
Johnson & Johnson And Harley-Davidson Inc Q2 Earnings Reports

Jul 18, 2017 | Value Walk

By Michelle Jones

The Johnson & Johnson Q2:F17 and Harley-Davidson Q2:F17 earnings reports were released before opening bell this morning. Johnson & Johnson posted adjusted earnings of $1.83 per share on $18.8 billion in sales, compared to the consensus estimates of $1.79 per share and $18.95 billion in revenue. In last year’s second quarter, the company posted $18.48 billion in revenue.
Harley-Davidson posted earnings of $1.48 per share on $1.58 billion in motorcycle and related products revenue. The consensus was looking for $1.38 per share in earnings on $1.6 billion in sales. In last year’s second quarter, the motorcycle maker reported $1.55 per share in earnings on $1.67 billion in sales.
Johnson & Johnson Q2:F17 earnings
Johnson & Johnson’s GAAP earnings per share fell to $1.40 from $1.43 per share in last year’s second quarter. Worldwide Consumer sales grew 1.7% year over year to $3.5 billion, just edging out the consensus at $3.4 billion. Worldwide Pharmaceutical sales ticked lower by 0.2% to $8.6 billion, while consensus had been looking for $8.7 billion. Medical device sales grew 4.9% to $6.7 billion, compared to the consensus of $6.7 billion.
Johnson & Johnson also adjusted its guidance for the full year. It now looks for sales to be between $75.8 billion and $76.1 billion, compared to the previous outlook of between $75.4 billion and $76.1 billion. The firm also boosted its adjusted earnings guidance to a range of $7.12 to $7.22 per share, from the previous range of $7 to $7.15 per share.
Following the Johnson & Johnson Q2:F17 earnings report, the company’s stock rose by as much as 1.4% to $134 in premarket trading this morning.
Harley-Davidson Q2:F17 earnings
Harley-Davidson shipped 81,388 motorcycles during the second quarter, a 6.7% decline from last year’s second quarter. Worldwide retail motorcycle sales fell 6.7% year over year. U.S. motorcycle sales fell 9.3%. The company’s U.S. market share stood at 48.5% in the 602cc-plus segment during the second quarter. International retail sales declined 2.3%.
Harley-Davidson also slashed its outlook for motorcycle shipments this year to a decline of between 6% to 8%. The company’s previous outlook had been “flat to down modestly.” The company expects motorcycle shipments during the third quarter to be down by 10% to 20%, which would be a range of 39,000 to 44,000.

After the Harley-Davidson Q2:F17 earnings report, the company’s stock ripped lower by as much as 8% to $47.84 in premarket trading this morning.

Return to headline | Return to top
Shares now down at $132.15 (JNJ) Johnson & Johnson Reports 2017

Jul 18, 2017 | First News 24

By Roy Scholtz

Johnson & Johnson (NYSE:JNJ):
Johnson & Johnson Reports 2017 Second-Quarter Results:.
The company is so far trading down by -0.37 percent from yesterday’s close.
Johnson & Johnson also declared a dividend for shareholders paid on Tuesday June 13th, 2017. The dividend payment was $0.840 per share for the quarter which is $3.36 annualized. This dividend represents a yeild of $2.53 which is the dividend as a percentage of the current share price. The ex-dividend date was Thursday the 25th of May 2017.
Johnson & Johnson, launched on November 10, 1887, is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates through three segments: Consumer, Pharmaceutical and Medical Devices. The Business’s primary focus is on products related to human health and well-being. The Business’s subsidiaries operated 119 manufacturing facilities, as of January 1, 2017. The Business’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom. The Company has over 230 operating companies, which conduct business around the world..
It is currently trading at $132.15 which is just over the 50 day moving average of $130.42 and which is marginally over the 200 day moving average of $122.68. The 50 day moving average moved up $1.73 and the 200 day average was up $9.47.
The P/E ratio is currently 22.21 and the market cap of the company is 355.99B. As of the latest earnings report the EPS was $5.95 and is projected to be $7.10 for the current year with 2,693,833,000 shares outstanding. Analysts expect next quarter’s EPS to be $1.78 and the next full year EPS is anticipated to be $7.67.
A few brokerages have released ratings on the stock of late. On May 15, 2017 the stock rating was changed to a “Overweight” in a report from JP Morgan which is up from the previous “Neutral” rating. On November 29 the company was rated “Equal-Weight” according to a Barclays report which was a cut from the previous “Neutral” rating.
September 13 investment analysts at Jefferies held the stock rating at “Hold” and raised the price expectation from $109.00 to $115.00. Argus Research upgraded the stock and lowered the price target on July 20 changing the price target from $114.00 to $113.00 and moving the rating from “Neutral” to “Hold”.

On July 20 the company was upgraded from “Neutral” to “Hold” and a price target of $113.00 was set in a report from Argus Research. On June 14 Jefferies kept the company rating at “Hold” but moved up the price target from $99.00 to $109.00.

Return to headline | Return to top
Johnson & Johnson shares advance as second quarter beats market expectations

Jul 18, 2017 | Proactive Investors

By Jamie Ashcroft

Johnson & Johnson (NYSE:JNJ) shares advanced almost 1% in Tuesday’s premarket deals after quarterly financials beat market expectations.
The consumer goods group reported quarterly earnings of US$1.83 per share, three cents per share better than Wall Street expected.
Revenue did not, however, meet market expectations. Second quarter sales amounted to US$18.8bn, which was an increase of 1.9% from the same period last year.
Johnson & Johnson did, though, increase its sales guidance for the full year up to a range of US$75.8bn to US$76.1bn.
Chief executive Alex Gorsky, in a statement, said: "Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year.”

Johnson & Johnson shares were changing hands at US$133.50 each, up US$1.35 or 1.02%.

Return to headline | Return to top
ANALYST ADVICE AND EARNINGS INSIGHT: JOHNSON & JOHNSON (JNJ), SEATTLE GENETICS, INC. (SGEN)

Jul 18, 2017 | Post Analyst

The recently concluded session had traders exchanging Johnson & Johnson (NYSE:JNJ)low level. Roughly 4.92 million shares changed hands compared to the three-month volume average 5.7 million shares. The first trade took place at $132.71 and the stock went down -0.34% to attain the closing price of $132.15.
Johnson & Johnson (JNJ) Analyst Opinion
Johnson & Johnson has a consensus outperform rating from 21 Wall Street analysts, and the number of shares currently sold short amount to at least 0.59% of shares outstanding. The stock sank -0.67% last month and is up 14.7 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover JNJ having a buy-equivalent rating. Analysts have placed a $133.39 price target on Johnson & Johnson, suggesting a 0.94% gain from recent close. It’s currently trading about -3.54% below its 52-week high.
Johnson & Johnson Earnings Surprise
Johnson & Johnson (JNJ) surprised the stock market in its last reported earnings when it earned $1.83 a piece versus the consensus-estimated $1.77. Its revenue totaled $18.04 billion down -0.38% from the previous quarter.
Johnson & Johnson (NYSE:JNJ) Intraday View
This stock (JNJ) is ahead of its 52-week low with 20.88%. Its last month’s stock price volatility remained 0.93% which for the week stands at 1%. The share price has moved backward from its 20 days moving average, trading at a distance of -1.06% and stays 1.58% away from its 50 days moving average. Over the last five days, shares have managed 0.46% gains and now is up 8.92% since hitting its 200-day moving average of $122.68. Johnson & Johnson (JNJ) has made its way to a 12-month gain of 7.44%.
Turning to Seattle Genetics, Inc. (NASDAQ:SGEN), its shares were trading at $53.73 a retreat of $0, on the trading floor. The stock, after opening at $53.89, touched a high of $54.45 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.6. Seattle Genetics, Inc. has 2 buy ratings, 8 holds and 0 sells even after the stock tumbled -28.7% from its high of $75.36 to a $7.72 billion market value through last close.
Seattle Genetics, Inc. (SGEN) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 2.57 to 2.57 during a month. Analysts set a 12-month price target of $58.2 a share. The target implies a 8.32% spike from where the shares are currently trading. Also, the current price highlights a discount of 39.59% to analysts’ high consensus price target.
Seattle Genetics, Inc. (NASDAQ:SGEN) Intraday Trading

The counter witnessed a trading volume of 0.68 million shares versus an average volume of 1.05 million shares during last trading session. Its last month’s stock price volatility remained 2.7% which for the week approaches 4.32%. The lowest price the stock reached in the last trading day was $53.61 and compares with the $41.34 52-week low. The stock recovered 29.97% since its low point and has performed 1.82% year-to-date.

Return to headline | Return to top
Johnson & Johnson Q2 Consumer Sales Rise 1.7%

Jul 18, 2017 | Happi

Johnson & Johnson is reporting sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%, according to the consumer healthcare giant.

Worldwide consumer sales of $3.5 billion for the second quarter 2017 represented an increase of 1.7% versus the prior year, consisting of an operational increase of 2.3% and a negative impact from currency of 0.6%. Domestic sales increased 7.4%, international sales decreased 2.2%, which reflected an operational decrease of 1.1% and a negative currency impact of 1.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 0.8%, domestic sales increased 1.2% and international sales decreased 2.3%. In this sector, worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by baby care products, partially offset by domestic over-the-counter products, including upper respiratory products and international anti-smoking aids, and Neutrogena beauty products.

Return to headline | Return to top
JNJ Stock: Johnson & Johnson Still a Top Pick for Long-Term Investors

Jul 18, 2017 | Income Investors

By Jing Pan

JNJ Stock Delivering Enormous Returns
The thing with dividend stocks like Johnson & Johnson (NYSE: JNJ) is that they don’t really work that well in a conversation at a cocktail party. When asked about your stock market investments, people will likely show more interest when you tell them about an electric car company or a smartphone maker rather than JNJ stock.
Even for investors that are seeking income, JNJ stock doesn’t seem to deserve special attention. Trading at $132.07 apiece, the company has an annual dividend yield of 2.54%. If you use any of the dividend screening tools available on the Internet today, you could easily find plenty of companies that provide much higher yields.
And yet Johnson & Johnson stock has been a favorite among long-term investors. If you bought 100 shares of JNJ stock 40 years ago, the investment would have cost you $6,912.00 back then. If you held onto those shares and reinvested all the dividends until today, take a guess on how much the investment is worth now?
$1,046,252.23. That translates to a return of over 15,000%.
You may think that JNJ stock was able to deliver such returns because of its more substantial dividends back in the day. And while the company is known for paying a steadily increasing stream of dividends, it was never an ultra-high yielder. As a matter of fact, Johnson & Johnson’s average dividend yield for the past 22 years has been just 2.27%. (Source: “JNJ Yield Chart – All History,” YieldChart.com, last accessed July 17, 2017.)
In other words, JNJ stock showed that you don’t need a double-digit yielder or a company that’s making “the next big thing” to make a decent return. A large, established company with a relatively boring business can also deliver enormous returns.
Of course, some will argue that for Johnson & Johnson stock, the “easy profits” have already been made and that past performance does not guarantee future results. Why should investors still consider JNJ stock right now?
Well, because the things that made Johnson & Johnson stock attractive 40 years ago still apply today.
Durable Competitive Advantage
Johnson & Johnson is in the healthcare sector. The company operates through three segments: Consumer, Pharmaceutical, and Medical Devices.
Brand strength is key to Johnson & Johnson’s success. The company was founded more than a century ago and has established itself as a leading healthcare brand in many countries around the world. JNJ earns around 70% of its sales from products that have a number-one or number-two global market share position. Note that when it comes to baby care, wound care, and personal care products, consumers are willing to pay a premium for well-known, high quality brands. With a huge presence in these major markets, Johnson & Johnson is well-positioned to continue its success.
Today, Johnson & Johnson has 250 operating companies in 60 countries. Its products are sold around the world. Last year, the company generated $71.9 billion of revenue. (Source: “Johnson & Johnson Reports 2016 Fourth-Quarter Results,” Johnson & Johnson, January 24, 2017.)
This means Johnson & Johnson can take advantage of economies of scale. Moreover, with its massive size, the company can afford to invest quite a bit in research and development–something that’s necessary for a company to remain competitive in biotech and pharmaceuticals. Last year, JNJ spent nearly $9.1 billion on research and development.
Don’t forget that the world’s elder population has grown substantially over the years, and the trend is expected to continue. This could be a huge catalyst for healthcare companies like Johnson & Johnson.
A Recession-Proof Business
There are plenty of companies making handsome profits today, but some of them are in cyclical businesses. If the economy enters a downturn–and it will at some point in the future, because the economy always moves in cycles–some companies may see their business decline.
If these companies are paying oversized dividends today, they may have trouble continuing to pay this much when the next recession arrives.
Obviously, income investors don’t want dividend cuts. The good news is that Johnson & Johnson is known for paying recession-proof dividends. As a matter of fact, the company has increased its quarterly dividend rate every year for the past 55 years.
But to be honest, I’m not really surprised. Johnson & Johnson is running one of the most recession-proof businesses on the planet. The demand for many of its brand name products, such as “Band-Aid” and “Tylenol,” are known to be stable no matter where we are in the economic cycle.
Good Value for Money
JNJ stock already had its rally. But because the company has also grown its business substantially over the decades, its valuations remain reasonable. Johnson & Johnson currently has a price-to-earnings (P/E) multiple of 22.23 times, which is lower than the S&P 500’s average P/E ratio of 26.04 times. Moreover, if you use the company’s expected earnings for next year, you’d see that JNJ stock has a forward P/E of just 17.25 times.
For these reasons, JNJ stock is still a top pick for long-term investors

Return to headline | Return to top
Johnson & Johnson (NYSE:JNJ) Issues FY17 Earnings Guidance

Jul 18, 2017 | Daily Political

By Trevor Kearing

Johnson & Johnson (NYSE:JNJ) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $7.12-7.22 for the period, compared to the Thomson Reuters consensus estimate of $7.11. The company issued revenue guidance of $75.8-76.1 billion, compared to the consensus revenue estimate of $75.65 billion.
Several analysts recently issued reports on the company. UBS AG reiterated a buy rating and issued a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Vetr upgraded Johnson & Johnson from a hold rating to a buy rating and set a $132.33 price target for the company in a report on Thursday, May 18th. Stifel Nicolaus reiterated a hold rating and issued a $128.00 price target (up from $124.00) on shares of Johnson & Johnson in a report on Thursday, May 18th. BidaskClub upgraded Johnson & Johnson from a buy rating to a strong-buy rating in a report on Saturday, June 17th. Finally, Wells Fargo & Company reiterated a market perform rating and issued a $135.00 price target (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Eleven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $133.65.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 132.15 on Tuesday. The stock’s 50 day moving average price is $130.42 and its 200-day moving average price is $122.68. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.00. The company has a market cap of $355.99 billion, a PE ratio of 22.21 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.87% and a return on equity of 26.50%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.74 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $7.10 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.54%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.47%.

Return to headline | Return to top
Johnson & Johnson (NYSE:JNJ) Announces Quarterly Earnings Results

Jul 18, 2017 | Ticker Report

By Stephan Byrd

Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings results on Tuesday. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04, Bloomberg Earnings reports. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same period in the prior year, the firm earned $1.74 EPS. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Johnson & Johnson updated its FY17 guidance to $7.12-7.22 EPS.
Shares of Johnson & Johnson (JNJ) opened at 132.15 on Tuesday. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.00. The company has a market cap of $355.99 billion, a PE ratio of 22.21 and a beta of 0.78. The company’s 50-day moving average price is $130.42 and its 200 day moving average price is $122.68.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. The ex-dividend date is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.54%. Johnson & Johnson’s payout ratio is 56.47%.
A number of institutional investors have recently made changes to their positions in JNJ. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $117,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares in the last quarter. Empirical Finance LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $144,000. Finally, Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the first quarter valued at $186,000. Institutional investors and hedge funds own 66.02% of the company’s stock.

Several brokerages recently issued reports on JNJ. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 price target (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Royal Bank Of Canada reiterated a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Jefferies Group LLC reiterated a “hold” rating and issued a $140.00 price target on shares of Johnson & Johnson in a report on Friday, June 16th. Finally, Morgan Stanley increased their price target on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Eleven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $133.65.

Return to headline | Return to top
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic

Jul 18, 2017 | The Motley Fool

By Dan Caplinger

Johnson & Johnson (NYSE:JNJ) owes much of its recent success to the strength of its pharmaceutical division. Even though the company also has extensive exposure to other parts of the healthcare field, including medical devices and over-the-counter consumer products, the drug business has been J&J's biggest growth area for years. Recently, though, Johnson & Johnson has seen its revenue growth become more sluggish, and that has some investors concernedabout whether the company is suffering through a temporary slow period or dealing with longer-term structural changes that could dampen its future prospects.
Coming into Tuesday's second-quarter financial report, Johnson & Johnson investors were looking for modest gains on the top and bottom lines, as well as some favorable comments about the recent acquisition of Actelion and its impact on the company going forward. J&J's drug unit had another weak quarter, with segment sales actually declining, but the healthcare specialist was optimistic about its ability to take full advantage of its current opportunities. Let's take a closer look at Johnson & Johnson and what its latest results mean for investors.

Revenue challenges continue for J&J
Johnson & Johnson's second-quarter financial results continued the troubling trends that shareholders have seen in recent quarters, although the news wasn't all bad. Revenue rose 1.9% to $18.84 billion, which was more than $100 million less than most investors had expected from the healthcare giant. Revenue was up just 1.6% to $17.77 billion, which was about half the growth rate that investors had wanted to see. GAAP earnings again declined from year-earlier levels, but after accounting for tax provisions, adjusted net income of $5.02 billion was up 3% from the second quarter of 2016. Adjusted earnings of $1.83 per share topped the consensus forecast among those following the stock for $1.80 per share.
Looking more closely at Johnson & Johnson's segments, the key pharmaceutical unit had mixed results. Overall segment sales fell 0.2%, with currency impacts putting enough downward pressure on the numbers to offset a 1% operational top-line increase. Domestic sales were down 2.6%, but international sales climbed 3.3% even when you include adverse foreign exchange conditions. J&J also blamed a one-time positive adjustment in the year-earlier quarter for some of the sluggishness this quarter. The company called out solid performance from cancer fighters Darzalex and Imbruvica, and it highlighted expanded indications for Darzalex and the FDA approval of plaque psoriasis treatment Tremfya earlier this month after the second quarter had ended.
J&J saw stronger results in its medical devices unit, although most of the gains were attributable to acquisitions. Sales rose nearly 5% including the purchase of Abbott Medical Optics. Without the purchase, worldwide sales would have been up 1.1%. However, consumer sales were also relatively weak, as gains of 1.7% came generally from acquisitions. Organic worldwide consumer sales fell 0.8%.

What's ahead for Johnson & Johnson?
CEO Alex Gorsky tried to emphasize operational efficiency and optimism about the future. "Our second-quarter results reflect strong adjusted earnings growth," Gorsky said, "and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year." The CEO highlighted J&J's strong drug pipeline and the new opportunities that the Actelion acquisition opens to help boost revenue going forward.
Johnson & Johnson also increased its guidance for the full 2017 year once again. A $300 million boost to revenue projections brought J&J's top-line target to $76.1 billion. An increase of between $0.07 and $0.12 per share in adjusted earnings guidance set a new range of $7.12 to $7.22 per share.
Still, Johnson & Johnson has to make more progress in order to fight the downward impact of aging blockbuster treatments. Anti-inflammatory treatment Remicade still accounts for more than a sixth of J&J's pharmaceutical sales, but it's dealing with competition from rival drug makers. The $250 million hit to sales was a 14% decline from year-ago levels, and it took big gains from both Darzalex and Imbruvica to offset Remicade's falling revenue.

Johnson & Johnson investors were had a modestly positive response to the news, and the stock rose almost 1% in pre-market trading following the announcement. Yet the report leaves unanswered exactly when and how J&J expects to stoke its growth back to the levels at which shareholders would be more comfortable. Until that strategic vision becomes more evident, many investors will remain nervous about Johnson & Johnson's ability to keep its leadership status atop the healthcare field.

Return to headline | Return to top
Johnson & Johnson Shares Slip Following Mixed Earnings

Jul 18, 2017 | 24/7 Wall Street

By Chris Lange

Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted $1.83 in earnings per share (EPS) on $18.8 billion in revenue. The second quarter from last year had $1.74 in EPS and $18.48 billion in revenue. Thomson Reuters has consensus estimates calling for $1.80 in EPS and $18.95 billion in revenue.
Operational sales results increased 2.9% with a negative impact from currency of 1%. This included domestic sales increases of 1.6%, while international sales rose 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%.
Johnson & Johnson’s segments reported for the quarter:
Worldwide consumer sales of $3.5 billion for the second quarter represented an increase of 1.7% versus the prior year, consisting of an operational increase of 2.3% and a negative impact from currency of 0.6%. Worldwide pharmaceutical sales of $8.6 billion for the second quarter represented a decrease of 0.2% versus the previous year with an operational increase of 1% and a negative impact from currency of 1.2%. Worldwide medical devices sales of $6.7 billion for the second quarter 2017 represented a gain of 4.9% versus the prior year consisting of an operational increase of 5.9% and a negative currency impact of 1.0%.
During the quarter, New Brunswick, New Jersey-based Johnson & Johnson announced the completion of the acquisition of Actelion, a leading biopharmaceutical company, for about $30 billion in cash.
In terms of guidance for the full fiscal year, J&J expects its sales to come in a range of $75.8 billion to $76.1 billion up from the previous level. Additionally, the company raised its EPS guidance to a range of $7.12 to $7.22. The consensus estimates are calling for $7.10 in EPS and $75.67 billion in revenue.
Alex Gorsky, chairman and chief executive officer, commented:
Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. The Actelion acquisition establishes a new therapeutic area as well as another engine for growth.

Shares of J&J were last trading down about 0.6% at $131.35, with a consensus analyst price target of $133.67 and a 52-week range of $109.32 to $137.00.

Return to headline | Return to top
Remicade is ready to fend off biosim No. 2, Johnson & Johnson executives say amid Q2 revenue miss

Jul 18, 2017 | FiercePharma

By Carly Helfand

Johnson & Johnson’s Remicade is holding its own against a U.S. biosimilar rival—so much so, the company says, that it’s not worried about a second entrant, which could arrive later this year.
While second-quarter sales of the blockbuster sank about 14% year-over-year to $1.35 billion, falling about $96 million short of analyst estimates, J&J blamed the miss on rebate accruals in the year-ago quarter. Factor those out, and Remicade is “down only about 5%,” CFO Dominic Caruso said on the company's second-quarter earnings call, adding that the shortfall is “much lower than us or any of you had expected” in the face of competition from Pfizer copy Inflectra.
Plus, only a piece of that 5% stemmed from market-share losses, Caruso said. There’s also impact from pricing, as well as patient-switching from Remicade to J&J’s Stelara in Crohn’s disease.
With that in mind, J&J isn’t too concerned about Samsung’s Renflixis, a second biosim approved by the FDA in April. For one, it’s still unclear when the product will launch. Samsung hasn't announced a price, either. And with managed care contracts already in place for the coming year, “we feel pretty good that Remicade erosion overall, even with the entrant of a new biosimilar, will be less than we previously expected,” he said.
Of course, the New Jersey drugmaker isn’t relying solely on Remicade to keep its autoimmune portfolio in check. Stelara's $983 million in sales beat consensus by $76 million as the drug grew its share in the overall immunology market by 1.4 points over 2016’s second quarter.
Plus, there's Tremfya, approved just last week. With only about a quarter of the psoriasis population now using next-gen treatments, CEO Alex Gorsky said there’s room for the brand-new med Tremfya to make a splash despite its trio of new-age rivals. The company also has rheumatoid arthritis med sirukumab coming up the pipeline.
“It does represent, again, a portfolio approach, and we think that’s why we’re especially prepared to mange through the Remicade biosimilars,” Gorsky told investors.
That portfolio will join cancer standouts Imbruvica and Darzalex, among other products, in propelling the company to a strong second half of the year, J&J predicts.
Tuesday, despite unveiling second-quarter sales of $18.8 billion that narrowly missed Wall Street's estimates, it raised the lower end of its 2017 revenue guidance to $75.8 billion to from $75.4 billion. The company tweaked EPS guidance, too, upping its range to $7.12 to $7.22 from a previous $7.00 to $7.15.

Return to headline | Return to top
J&J: Remicade holding up better than expected

Jul 19, 2017 | BioPharma Dive

By Jacob Bell

Dive Brief:
Johnson & Johnson's blockbuster anti-inflammatory treatment experienced a double-digit drop in sales during the second quarter, but the big pharma cautioned investors not to place too much of that decline on biosimilar competition.
Remicade (infliximab), approved for several indications including Crohn's disease and ulcerative colitis, brought in $1.06 billion during the second quarter, down 14% from the same period in 2016. Since last April, the Food and Drug Administration has approved copycat biologics to the drug: Celltrion's Inflectra (infliximab-dyyb) and Samsung Bioepis’ Renflexis (infliximab-abda).
But during a Tuesday earnings call, Johnson & Johnson execs said the sales decrease seen with Remicade — as well as the company's overall immunology portfolio — was largely due to approximately $170 million worth of rebate adjustments from the second quarter last year. Excluding that factor, Remicade sales were down about 5%.

Dive Insight:
"That 5% down has some impact of price, some minor impact of share erosion, and we see some conversion of Remicade ... to Stelara in Crohn's disease," Johnson & Johnson's Chief Financial Officer Dominic Caruso said on the call, adding that his company and industry analysts had predicted a much larger decline, "which we all targeted to be somewhere between 10% and 15%."
Biosimilars have just recently squeezed out a foothold in the U.S., with only a handful approved so far and many still unable to launch on the market due to legal issues. Stateside drugmakers, however, are well aware of the potential of those drugs to disrupt markets and their bottom lines.
For the few pharmaceutical companies — Johnson & Johnson, Amgen and AbbVie — that are already experiencing competition from copycat biologics, solidifying their products' market shares or revamping pipelines and portfolios have been key strategies for quelling investor concerns.
Johnson & Johnson execs, for instance, underscored the potential for the company's recently green lit psoriasis drug Tremfya (guselkumab) and sirukumab, a rheumatoid arthritis treatment filed for FDA approval last September, to breathe new life into the immunology portfolio.
Noteworthy, though, is the fact that Johnson & Johnson is in the unique position of having two biosimilars to contend with. Samsung Bioepis’ Renflexis received U.S. approval a few months ago, and while it hasn't hit the market yet, it's another thing the big pharma will have to keep in its sights.
"In terms of what impact that might have, I think that all depends on the degree to which they discount that product and the significance of which they discount that product," Caruso said. "But I would say largely for this year, we have all our contracting in place with all the managed care organizations, so we feel pretty good that Remicade erosion overall, even with the entrance of a new biosimilar, will be less than expected."
It would appear that the drugmaker has convinced at least some investors.

"The business faces some near-term challenges, including pressure on Pharma from prior period gross to net adjustments, as well as slowing growth on Remicade, Zytiga and Invokana," investment firm Jefferies wrote in a July 14 note. "However, we think US biosimilars may have a smaller than expected impact on Remicade and that there are some notable opportunities in the pipeline that may be underappreciated."

Return to headline | Return to top
Johnson & Johnson Is Ready to Break Out in a Big Way Despite Lackluster Sales Growth (VIDEO)

Jul 18, 2017 | The Street

By Roberto Pedone

Pharmaceutical player Johnson & Johnson (JNJ) announced earnings this morning before the opening bell for the second-quarter of 2017, and there's a good reason to be bullish on the stock despite incremental sales growth.
The company announced sales of $18.8 billion for the second quarter of 2017, which was an increase of just 1.9% compared to the second quarter of 2016. Obviously, this low sales growth isn't enough to get investors excited, but the silver lining in this earnings report was the guidance forecast for the rest of 2017.
Johnson & Johnson raised its 2017 profit forecast to a range of $7.12 to $7.22 per share, from $7.00 to $7.15 per share. The company also raised its full-year 2017 sales guidance from $75.8 billion to $76.1 billion. Another silver lining can be found when the company said its full-year 2017 guidance does not include any potential U.S. tax reform.
Johnson & Johnson's comments on future sales should keep investor interest in the stock high, so now let's turn to the chart so I can highlight a very attractive setup that's developing quickly post-earnings.
If you take a look at the chart for Johnson & Johnson, you'll notice that this stock has been uptrending strong over the last six months, with shares moving higher off its low of $109.31 to its new 52-week high of $137 a share. During that uptrend, this stock has been consistently making higher lows and higher highs, which is bullish technical price action. That strong uptrend combined with the bullish sales forecast this morning is now quickly pushing this stock within range of triggering a major breakout trade.
Traders should now look for long-biased trades if this stock manages to clear some near-term overhead resistance levels at its 20-day moving average of $133.37 a share to $134.06, and then once it takes out its 52-week high of $137 a share with strong volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 5.68 million shares.
If that breakout triggers soon, then this stock will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $140 to $145, or even $150 to $155 a share.
Traders can use the 50-day moving average of $130.22 a share as a possible stop to exit the stock if that breakout doesn't trigger, or you can also use some more key near-term support levels at $126 to $125 a share as your stop.
J&J's shares rose 1.9% to $134.68 early Tuesday afternoon.

Return to headline | Return to top
Johnson & Johnson (JNJ) Issues FY17 Earnings Guidance

Jul 18, 2017 | Transcript Daily

By Lauren Steadman

Johnson & Johnson (NYSE:JNJ) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $7.12-7.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.11. The company issued revenue guidance of $75.8-76.1 billion, compared to the consensus revenue estimate of $75.65 billion.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 132.15 on Tuesday. The firm has a market capitalization of $355.99 billion, a price-to-earnings ratio of 22.21 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.00. The company’s 50-day moving average price is $130.42 and its 200 day moving average price is $122.68.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 EPS. On average, equities research analysts forecast that Johnson & Johnson will post $7.10 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.54%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.47%.
JNJ has been the topic of several recent research reports. J P Morgan Chase & Co upgraded Johnson & Johnson from a neutral rating to an overweight rating and boosted their price target for the company from $123.64 to $140.00 in a research report on Monday, May 15th. Vetr cut Johnson & Johnson from a buy rating to a hold rating and set a $128.82 price target on the stock. in a research report on Monday, May 15th. BTIG Research restated a hold rating on shares of Johnson & Johnson in a research report on Wednesday, April 19th. BidaskClub upgraded Johnson & Johnson from a buy rating to a strong-buy rating in a research report on Saturday, June 17th. Finally, Cowen and Company reiterated a buy rating and set a $143.00 target price (up previously from $138.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Eleven analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $133.65.
Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Return to headline | Return to top
Johnson & Johnson Is Delivering

Jul 18, 2017 | Seeking Alpha

By Quad 7 Capital Research

Summary
Earnings are out and key metrics are discussed.
Currency issues are back.
Actelion should ramp up second half sales.

Johnson & Johnson (NYSE:JNJ) has just reported earnings which once again continue to impress here in 2017 which I have described as a key year for the company. What we need to see are solid and stable results each quarter with the realization that JNJ is a slow growing, dividend paying machine. It is a great name to own in a retirement account long-term. The company continues to grow earnings but you have to pick your spots to enter. When the name dips you have to seize the opportunity, and so long as earnings continue to be strong, the name will just continue to edge higher.
So how did the company do on the earnings front? The company's most recent quarter saw sales of $18.84 billion. This was a slight uptick in sales of 1.9% year-over-year. I was a bit surprised that this figure missed estimates slightly by $110 million. Like many other domestic U.S. companies, the changes in currency year-over-year are having a negative impact on the absolute numbers. That fact is that businesses with a lot of international business are hurting from the stronger dollar. Taken independently, operational sales results increased 2.9% and the negative impact of currency was 1.0%.
On an absolute basis, domestic sales increased 1.6%, while international sales were up just 2.3%. Why? Well, this perceived weakness in international sales reflects actual operational growth of 4.4%, which is strong but also included a negative currency impact 2.1%. Johnson & Johnson is one of the harder hit companies by negative currency impacts, but the magnitude of the currency impacts seems to be decreasing each quarter, however, the last few months the dollar has weakened and as such, the impact of currency ticked up versus last quarter. Still the trend is lower in the last two years, barring this quarter. That is a trend that I have detected in the last year and a half, with this and other companies with a strong international presence.
The company itself continues to move forward, but investors want growth. That is what they are looking for. Well, on an operational basis, worldwide sales increased 0.5%, domestic sales dropped 1.0% but international sales rose 2.0%. This excludes the impacts of acquisitions and sales over the last year. Taking into account the company's operational expenses and sales data, the company saw net earnings come in at $3.8 billion. Taking into account the existing number of shares this translates to net earnings per share of $1.40. After further taking into account special items, adjusted net earnings were $5.0 billion and adjusted earnings per share were $1.83. The adjusted earnings per share rose 5.2% over last year. The $1.83 in adjusted earnings beat analyst estimates by $0.03. The company continues to deliver. Alex Gorsky, chairman and CEO, said:
"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA™ as well as the submission and approval of several key line extensions. The Actelion acquisition establishes a new therapeutic area as well as another engine for growth and we are pleased to welcome the Actelion colleagues to the Johnson & Johnson Family of Companies. Together with all of our businesses, we will continue to transform the lives of patients around the world."
The quarter was light on sales but there was once again another profit beat. The big news obviously is the Actelion acquisition which opens a new growth path. Sales missed the mark on domestic weakness but this has been a recurring theme. Still we have to keep an eye on that going forward. Looking ahead, the company is including the Actelion purchase in its outlook. JNJ sees 2017 sales of $75.4 billion to $76.1 billion. This continues to reflect expected operational growth in the range of 4.0% to 5.0%. Adjusted earnings guidance for full-year 2017 is $7.00 to $7.15 per share. Expect to see sales ramp up in the second half of the year as Actelion is more thoroughly incorporated. With the fact that the dividend will keep growing, and earnings continue to be solid, I continue to recommend buying on pullbacks.
Note from the author: Quad 7 Capital has been a leading contributor with Seeking Alpha since early 2012. If you like the material and want to see more, scroll to the top of the article and hit "follow." Quad 7 Capital also writes a lot of "breaking" articles that are time sensitive. If you would like to be among the first to be updated, be sure to check the box for "Email alerts" under "Follow."

Return to headline | Return to top
Johnson & Johnson Raises 2017 Sales, Profit Estimate

Jul 19, 2017 | SenegalActu

By Mercedes Poole

Tiedemann Wealth Management Llc increased Johnson & Johnson (JNJ) stake by 49.88% reported in 2016Q4 SEC filing. It is positive, as 6 investors sold Catalyst Pharmaceuticals Inc shares while 12 reduced holdings. Johnson & Johnson now has $354.54B valuation. The stock rose 0.05% or $0.02 reaching $40.24. About 2.40 million shares traded.
Johnson & Johnson (NYSE:JNJ) issued an update on its FY17 earnings guidance on Tuesday morning. It has underperformed by 4.16% the S&P500. (NYSE:EFX) stake by 64,011 shares to 2,162 valued at $256,000 in 2016Q4. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. Its up 0.12, from 0.82 in 2016Q3. 121 funds opened positions while 478 raised stakes. UBS initiated the shares of JNJ in report on Tuesday, September 22 with "Buy" rating. Pinnacle Liability Co accumulated 16,301 shares. Zacks Invest holds 586,807 shares. Wellington Management Limited Liability Partnership invested in 1.01% or 34.80 million shares. Davidson Investment Advisors holds 139,218 shares. Bkd Wealth Ltd Liability has invested 0.52% of its portfolio in Johnson & Johnson (NYSE:JNJ). Kanaly Tru stated it has 0.45% of its portfolio in Home Depot Inc (NYSE:HD). Alyeska Invest Group Inc LP accumulated 143,466 shares. Td Asset Mgmt Inc reported 0.56% in Johnson & Johnson (NYSE:JNJ). Montecito Bank owns 1,263 shares. Moreover, Founders Cap Mgmt Ltd Com has 3.47% invested in Johnson & Johnson (NYSE:JNJ) for 55,538 shares. Lvm Management Mi invested in 3.64% or 114,288 shares. Numeric Invsts Limited Liability Company has 88,600 shares for 0.11% of their portfolio. Connor Clark Lunn Mngmt Ltd has 347,225 shares.
Analysts await Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report earnings on August, 8. Out of 2 Wall Street analysts rating UDR, 1 give it "Buy", 1 "Sell" rating, while 0 recommend "Hold". Citigroup Inc. had 76 analyst reports since July 21, 2015 according to SRatingsIntel. Guggenheim upgraded the shares of C in report on Friday, August 28 to "Buy" rating. The company was downgraded on Thursday, October 20 by Sandler O'Neill. RBC Capital Markets maintained Citigroup Inc (NYSE:C) rating on Thursday, June 22. Stifel Nicolaus reiterated a "hold" rating and set a $128.00 target price (up from $124.00) on shares of Johnson & Johnson in a research report on Thursday, May 18th. (NYSE:UDR) to report earnings on July, 26 after the close. They expect $1.79 earnings per share, up 2.87% or $0.05 from last year's $1.74 per share. HD's profit will be $2.66 billion for 17.37 P/E if the $2.21 EPS becomes a reality.
The company has mean EPS estimate of 1.69 reported by 16 number of analyst for the quarter ending Current Qtr.(Jun2017).
Investors sentiment increased to 1.12 in Q4 2016. $6.18 million worth of stock was sold by Duato Joaquin on Friday, March 3. Forese James A. sold $3.30 million worth of stock or 55,436 shares. $2.58 million worth of stock was sold by Stoffels Paulus on Wednesday, February 15. HOLIFIELD MARK had sold 48,769 shares worth $7.65 million on Wednesday, May 17. Deep Value Etf (DVP) was reduced too. "Home Depot" on July 13, 2017. It is down 18.83% since July 18, 2016 and is uptrending.
Since February 1, 2017, it had 0 insider purchases, and 5 sales for $14.98 million activity.
Since the start of the New Year, Johnson & Johnson (NYSE:JNJ) shares have seen a move of 15.09%.
Several research analysts have commented on JNJ shares. Johnson & Johnson accounts for 2.2% of Somerset Trust Co's portfolio, making the stock its 4th largest position.
Legacy Private Trust, which manages about $736.63 million US Long portfolio, decreased its stake in Vanguard Index Fds (VXF) by 16,940 shares to 49,145 shares, valued at $4.71M in 2016Q4, according to the filing. It also upped Chevron Corp New Com (NYSE:CVX) stake by 5,268 shares and now owns 238,468 shares.
In the last reported quarter, Johnson & Johnson reported its Actual EPS (earnings per share) of $1.83/share where most of the analysts working on this stock were estimating the EPS to be $1.77/share. Therefore 100% are positive. As per Monday, December 19, the company rating was upgraded by Morgan Stanley. The company was reinitiated on Monday, October 5 by Piper Jaffray. Finally, Jefferies Group LLC reissued a "hold" rating and issued a $145.00 price objective (up previously from $140.00) on shares of Johnson & Johnson in a research report on Friday. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Tuesday, June 14. BMO Capital Markets maintained Johnson & Johnson (NYSE:JNJ) on Monday, July 10 with "Buy" rating. The stock now has a consensus rating of "Hold" and a consensus target price of $133.65.

Return to headline | Return to top
Johnson & Johnson (JNJ) Announces Quarterly Earnings Results

Jul 19, 2017 | Stock Observer

By George Bondi

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04, Bloomberg Earnings reports. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period last year, the company earned $1.74 earnings per share. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. Johnson & Johnson updated its FY17 guidance to $7.12-7.22 EPS.
Shares of Johnson & Johnson (JNJ) opened at 132.15 on Tuesday. The stock has a 50 day moving average price of $130.42 and a 200-day moving average price of $122.68. The firm has a market capitalization of $355.99 billion, a PE ratio of 22.21 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.00.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.54%. Johnson & Johnson’s payout ratio is presently 56.47%.
Several analysts have commented on JNJ shares. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC reissued a “hold” rating and issued a $135.00 price objective (down from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 15th. Barclays PLC restated an “equal weight” rating and issued a $130.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Eleven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $133.65.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the period. Landmark Financial Advisors LLC raised its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Landmark Financial Advisors LLC now owns 1,948 shares of the company’s stock valued at $224,000 after buying an additional 10 shares during the period. Lbmc Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% in the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after buying an additional 14 shares during the period. Berson & Corrado Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock valued at $353,000 after buying an additional 19 shares during the period. Finally, Cascade Investment Advisors Inc. raised its position in shares of Johnson & Johnson by 0.3% in the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock valued at $932,000 after buying an additional 23 shares during the period. 66.02% of the stock is currently owned by institutional investors.

Return to headline | Return to top
Johnson & Johnson (JNJ) Issues FY17 Earnings Guidance

Jul 19, 2017 | Steelers Lounge

By James Hoffman

The Sva Plumb Wealth Management Llc holds 94,891 shares with $10.93M value, down from 98,094 last quarter. The stock has a market cap of $355.99 billion, a price-to-earnings ratio of 22.21 and a beta of 0.78.
Johnson & Johnson (JNJ) traded down 0.34% during midday trading on Monday, reaching $132.15. About 12,962 shares traded. It is down 18.83% since July 18, 2016 and is uptrending. It has outperformed by 18.90% the S&P500.
Cohen Capital Management Inc.'s holdings in Johnson & Johnson were worth $7,339,000 as of its most recent filing with the SEC.
Earnings Beat: JNJ beat on second quarter earnings - the company reported EPS of $1.83 while our consensus called for EPS of $1.79. Johnson & Johnson now has $352.31B valuation. Its last month's stock price volatility remained 0.93% which for the week stands at 1%. About 2.40 million shares traded. Wells Fargo & Company reiterated a "market perform" rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. It has underperformed by 4.16% the S&P500.
Without the purchase, worldwide sales would have been up 1.1%. Its down 0.05, from 0.85 in 2016Q3. 87 funds opened positions while 199 raised stakes. Prelude Mgmt Limited Liability holds 4,201 shares or 0.06% of its portfolio.
J&J's shares rose 1.9% to $134.68 early Tuesday afternoon. Franklin Street Nc accumulated 27,020 shares. Blackrock Advisors Ltd Liability Com has 12,442 shares. Jnba Fincl Advsr owns 200 shares. Barrett Asset Management Ltd Liability Com, a New York-based fund reported 285,989 shares. Deep Value Etf (DVP) was reduced too. First Heartland Consultants holds 0.16% or 3,828 shares in its portfolio. Life Tru Co invested in 3,923 shares. Berson & Corrado Investment Advisors LLC raised its position in Johnson & Johnson by 0.7% in the first quarter. M&T National Bank Corp invested in 649,254 shares.
Sales of diabetes drug Invokana, another key J&J product, plunged 23% to $295 million in the quarter. Shares for $30,725 were sold by Timmermans Ted T on Tuesday, May 16. Waters Parkerson & Company increased Fortune Brands Home & Sec Inc (NYSE:FBHS) stake by 9,685 shares to 393,044 valued at $21.01 million in 2016Q4. Analysts expect Equity LifeStyle Properties, Inc. Fission Uranium Corp had 2 analyst reports since September 4, 2015 according to SRatingsIntel. Barclays Capital maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, April 20 with "Overweight" rating. Guggenheim upgraded the shares of C in report on Friday, August 28 to "Buy" rating. Johnson & Johnson (JNJ) now has P/E (Price to Earnings) ratio of 22.29 while the company's industry has 13.61 P/E and the sector P/E is 17.23. JMP Securities has "Market Outperform" rating and $28 target. The stock of Citigroup Inc (NYSE:C) earned "Neutral" rating by Credit Suisse on Monday, December 21. The rating was initiated by Topeka Capital Markets with "Buy" on Tuesday, May 24.
The firm has "Outperform" rating given on Wednesday, January 25 by RBC Capital Markets. Since the start of the New Year, Johnson & Johnson (NYSE:JNJ) shares have seen a move of 15.09%. However, this comes in below analysts' revenue estimate of $18.95 billion. Analysts await Home Depot Inc (NYSE:HD) to report earnings on August, 15 before the open. During the same quarter previous year, the company posted $1.68 earnings per share. SNE's profit will be $605.49 million for 20.96 P/E if the $0.48 EPS becomes a reality. It also came in above Wall Street's earnings per share estimate of $1.80 for the quarter. Therefore 50% are positive. Catalyst Pharmaceuticals had 3 analyst reports since April 26, 2016 according to SRatingsIntel. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Tuesday, June 14. As per Thursday, July 14, the company rating was maintained by Jefferies. BidaskClub upgraded Johnson & Johnson from a buy rating to a strong-buy rating in a research report on Saturday, June 17th. The firm earned "Buy" rating on Wednesday, October 19 by UBS. Total cash per share on the most recent quarter is 14.61. S&P Research maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, October 14. The stock of Wix.Com Ltd (NASDAQ:WIX) has "Outperform" rating given on Thursday, August 6 by RBC Capital Markets.
Vetr downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating and set a $128.82 price objective on the stock.in a research report on Monday, May 15th. Duato Joaquin sold 50,000 shares worth $6.18M. Investors of record on Tuesday, August 29th will be given a $0.84 dividend. It is positive, as 63 investors sold JNJ shares while 834 reduced holdings. American has invested 0.47% in Johnson & Johnson (NYSE:JNJ). Swarthmore Grp Inc reported 0.09% stake. Schafer Cullen Management stated it has 2.02% in Johnson & Johnson (NYSE:JNJ).
Crow Point Prns Ltd Company owns 0.03% invested in Wix.Com Ltd (NASDAQ:WIX) for 3,762 shares. Waters Parkerson & Limited Liability Co owns 165,527 shares. Tdam Usa reported 360,313 shares. Laurion Cap Management Lp stated it has 78,181 shares. Orbimed Advsrs Lc invested in 1.26% or 858,000 shares. Fidelity reported 58,480 shares or 1.54% of all its holdings. Hengehold Capital Mgmt Llc holds 0.79% or 22,453 shares. $2.45M worth of Johnson & Johnson (NYSE:JNJ) was sold by Ullmann Michael H on Wednesday, February 1.

Return to headline | Return to top
Johnson & Johnson (NYSE:JNJ) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Jul 19, 2017 | WKRB News and Analysis

By Kristian Gore

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04, Bloomberg Earnings reports. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.87% and a return on equity of 26.50%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.74 earnings per share. Johnson & Johnson updated its FY17 guidance to $7.12-7.22 EPS.
Johnson & Johnson (NYSE:JNJ) opened at 134.46 on Wednesday. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.00. The stock has a market cap of $362.21 billion, a price-to-earnings ratio of 22.60 and a beta of 0.78. The firm’s 50-day moving average is $132.45 and its 200 day moving average is $124.27.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.47%.
Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter worth approximately $117,000. Harel Insurance Investments & Financial Services Ltd. increased its position in Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares in the last quarter. Empirical Finance LLC bought a new position in Johnson & Johnson during the fourth quarter worth approximately $144,000. Finally, Ullmann Financial Group Inc. bought a new position in Johnson & Johnson during the first quarter worth approximately $186,000. 66.02% of the stock is owned by institutional investors.
A number of brokerages have recently commented on JNJ. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 target price for the company. in a research report on Monday, May 8th. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 target price (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. UBS AG reiterated a “buy” rating and issued a $136.00 target price on shares of Johnson & Johnson in a research report on Monday, May 15th. J P Morgan Chase & Co upgraded shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and increased their target price for the company from $123.64 to $140.00 in a research report on Monday, May 15th. Finally, BidaskClub cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Eleven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $133.65.

Return to headline | Return to top
Johnson & Johnson Raises Yearly Sales, Profit Outlook

Jul 19, 2017 | The Street

By Amanda Schiavo

Johnson & Johnson (JNJ) increased its expectations for its yearly profit and sales outlook, after reporting 2017 second quarter financial results on Tuesday morning.
Shares are higher in late morning trading.
The healthcare products and services company is now expecting adjusted earnings to come in between $7.12 and $7.22 per share, above its previous guidance range between $7 and $7.15.
Sales are expected to be between $75.8 billion and $76.1 billion for the year, compared to the previous estimate of $75.4 billion to $76.1 billion.
Sales and earnings are expected to climb in the second half of the year as the company incorporates new acquisitions and launched new products.
For the second quarter Johnson & Johnson reported adjusted earnings of $1.83 per share on revenue of $18.8 billion.

Return to headline | Return to top
Johnson & Johnson Signals It Could Make Additional Divestitures

Jul 19, 2017 | The Street

By Armie Margaret Lee

More divestitures could be in Johnson & Johnson's (JNJ) future.
On an earnings call on Tuesday, July 18, chief financial officer Dominic Caruso noted that among Johnson & Johnson's priorities is to actively manage its portfolio to maximize value.
"Our ongoing reviews suggest we currently have more opportunity to divest some nonstrategic businesses which will result in higher other income gains," Caruso said.
Asked by an analyst for more details on the potential divestitures, Caruso said they are smaller brands across multiple businesses.
"We'll have to see whether we can get the right value for those assets before we actually execute on them," he said.
Among the divestitures that have already been announced this year was the sale of Johnson & Johnson's Codman Neurosurgery business to Integra Lifesciences Holdings Corp. (IART) for $1.05 billion. The deal is expected to close in the fourth quarter.
In June, Johnson & Johnson units Cilag GmbH International and Janssen Pharmaceutica NV sold a portfolio of European over-the-counter products to Trimb Healthcare AB.
Meanwhile, Johnson & Johnson continues to review options for its diabetes care business, company officials said Tuesday. Johnson & Johnson said in January it was looking at potential strategic options for the diabetes care unit, including LifeScan, Animas and Calibra Medical.
New Brunswick, N.J.-based Johnson & Johnson on Tuesday reported second-quarter earnings that beat expectations and revenue that came in below consensus estimates. The company reported adjusted earnings per share of $1.83, up 5.2% from the same period a year ago, and revenue of $18.8 billion, up 1.9% year-over-year. Analysts surveyed by Bloomberg had forecast adjusted EPS of $1.79 on revenue of $18.9 billion.

Return to headline | Return to top
These 2 Drug Giants In Buy Range Just Beat Earnings Views

Jul 19, 2017 | Investors Business Daily

By Allison Gatlin

Two stocks in buy range — Swiss drugmaker Novartis (NVS) and Dow industrials component Johnson & Johnson (JNJ) — both reported better-than-expected second-quarter earnings early Tuesday.
Novartis earned $1.22 a share excluding various items, down from $1.23 a year earlier. Sales fell 2% to $12.24 billion amid growing generic competition for cancer drug Gleevec. But the numbers were better than analyst forecasts for earnings of $1.16 a share and revenue of $12.1 billion.
Excluding Gleevev/Gilvec, sales of cancer drugs rose 9%, excluding the impact of foreign exchange rates. Bone marrow stimulant Promacta/Revolade pulled in $210 million, up 35%. Sales of advanced melanoma and advanced lung cancer combination Tafinlar and Mekinist grew 28% to $216 million.
Consentyx was another driver, growing 90%, excluding the impact of foreign exchange rates, to $490 million, Novartis said in a news release. The drug is approved to treat plaque psoriasis, psoriatic arthritis and inflammation of the spine and joints.
Despite broadening competition in multiple sclerosis treatments that includes the likes of Biogen(BIIB), Roche (RHHBY) and Sanofi (SNY), Novartis' MS drug Gilenya brought in $837 million, up 5% excluding the impact of foreign exchange rates. But Celgene (CELG) is now working on a drug that could directly rival Gilenya.Are you getting the most out of IBD? Our Getting Started Guide can help!
Novartis' Alcon eye-care unit reported a small sales increase to $1.5 billion. Novartis raised its full-year Alcon sales target slightly, hinting at a possible spinoff for the division. Sales of contact lenses grew for the fifth consecutive quarter, Evercore analyst Umer Raffat noted in a report.
On the stock market today, Novartis ended the day up 1.8% to 84.77. Novartis cleared an 82.04 cup-with-handle buy point last month. The 5% chase zone runs to 86.14.
Johnson & Johnson, meanwhile, cleared a flat-base entry of 129.10 in early June. J&J stock rose 1.8% to finish Tuesday's regular session at 134.46, after the company reported adjusted earnings of $1.83 a share, up 28% vs. a year earlier and beating analyst views by 4 cents. Revenue was $18.84 billion, up slightly from a year earlier but just missing views of $18.9 billion.
IBD'S TAKE: Small biotechs performed well over the past few weeks amid a biotech rally that saw the sector hit a 17-month high in June. Head to IBD's Technology page for a look at who looked strong in the pop.
Worldwide pharma sales of $8.6 billion declined a fraction vs. the year-ago period, and missed for the third straight quarter, RBC analyst Glenn Novarro told clients in a note. U.S. drug sales dipped 2.6%, but 3.3% growth in sales outside the U.S. helped to partially offset that decline.
Meanwhile, consumer and medical devices segments grew 1.7% and 4.9%, respectively. Though pharma sales missed Novarro's estimate by $170 million, revenues from J&J's consumer and medical devices units were in line with expectations.
J&J sees full-year earnings of $7.12-$7.22 a share, with revenue of $75.8 billion to $76.1 billion. Analysts see earnings of $7.10 a share with revenue of $75.71 billion. Novarro says the guidance is likely taking advantage of favorable foreign exchange rates in the second half of the year.

Return to headline | Return to top

Television

CNBC Squawk Box

Jul 18, 2017 | CNBC

https://app.criticalmention.com/app/#clip/view/28342076?token=74e6582b-8cc9-4c79-b93f-58af3b88ebb1

Return to headline | Return to top
CNBC Squawk Box

Jul 18, 2017 | CNBC

https://app.criticalmention.com/app/#clip/view/28342136?token=74e6582b-8cc9-4c79-b93f-58af3b88ebb1

Return to headline | Return to top
CNBC Squawk Box Clip (Analyst Analysis)

Jul 18, 2017 | CNBC

https://app.criticalmention.com/app/#clip/view/28342185?token=74e6582b-8cc9-4c79-b93f-58af3b88ebb1

Return to headline | Return to top
Bloomberg Daybreak: Americas

Jul 18, 2017 | Bloomberg

https://app.criticalmention.com/app/#clip/view/28342899?token=74e6582b-8cc9-4c79-b93f-58af3b88ebb1

Return to headline | Return to top
CNBC Squawk Box – Jim Cramer

Jul 18, 2017 | CNBC

https://app.criticalmention.com/app/#clip/view/28343630?token=74e6582b-8cc9-4c79-b93f-58af3b88ebb1

Return to headline | Return to top
CNBC Squawk on the Street

Jul 18, 2017 | CNBC

https://app.criticalmention.com/app/#clip/view/28343958?token=74e6582b-8cc9-4c79-b93f-58af3b88ebb1

Return to headline | Return to top
CNBC Mad Money with Jim Kramer

Jul 19, 2017 | CNBC

By CNBC

https://app.criticalmention.com/app/#clip/view/28357262?token=8587395d-ab98-4283-b38f-8c565b2512f4

Return to headline | Return to top
CNBC Street Signs

Jul 19, 2017 | CNBC

https://app.criticalmention.com/app/#clip/view/28357219?token=8587395d-ab98-4283-b38f-8c565b2512f4

Return to headline | Return to top

Add recipients

Suggested